NCT01674972

Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 102 (actual)
• Sponsor: University Hospital, Basel, Switzerland · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM. Insulin resistance is a pathophysiologic hallmark of non-alcoholic fatty liver disease (NAFLD). The incretin effect in patients with NAFLD has not been studied. The aim of this study is to quantify GLP-1 secretion in response to oral glucose tolerance test (oGTT) in patients with NAFLD compared to healthy controls. The results of this study will expand the knowledge of the pathophysiology of NAFLD and serve as a rational for potential future treatment strategies.

Detailed description

Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin responses to oral glucose challenge

Conditions

• Non Alcoholic Fatty Liver Disease
• Non Alcoholic Steatohepatitis

Interventions

Type	Name	Description
OTHER	Oral glucose tolerance test	Oral intake of 75 g glucose after overnight fast

Timeline

• Start date: 2011-01-01
• Primary completion: 2012-04-01
• Completion: 2012-06-01
• First posted: 2012-08-29
• Last updated: 2012-08-29

Locations

1 site across 1 country: Switzerland